Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 6/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 3/20 | 0.31 |
| ▸ | RET | P07949 | 3/20 | 0.31 |
| ▸ | ROS1 | P08922 | 3/20 | 0.31 |
| ▸ | FLT3 | P36888 | 3/20 | 0.31 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205975 | 1.00 | BTK (0.32) | BTKEGFRPDE5AOGARET | |
| SCHEMBL29173396 | 0.93 | BTK (0.34) | BTKRETROS1FLT3EML4 | |
| SCHEMBL30206121 | 0.93 | BTK (0.34) | BTKRETROS1FLT3EML4 | |
| SCHEMBL24944775 | 0.92 | EML4 (0.39) | BTKEGFRRETROS1FLT3 | |
| SCHEMBL24944774 | 0.92 | EML4 (0.39) | BTKEGFRRETROS1FLT3 | |
| SCHEMBL24944777 | 0.92 | EML4 (0.39) | BTKEGFRRETROS1FLT3 | |
| Formic Acid SCHEMBL29173298 | 0.89 | RET (0.37) | EGFRRETROS1FLT3EML4 | |
| Formic Acid SCHEMBL30205516 | 0.89 | RET (0.37) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL30205942 | 0.85 | CDK2 (0.39) | FLT3 | |
| SCHEMBL29173448 | 0.85 | SYK (0.36) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |